Risk of congenital heart diseases associated with NAT2 genetic polymorphisms and maternal polycyclic aromatic hydrocarbons exposure

Jing Tao,Nana Li,Zhen Liu,JinPing Qiu,Ying Deng,Xiaohong Li,Ming Chen,Jing Yu,Jun Zhu,Ping Yu,Yanping Wang
DOI: https://doi.org/10.1002/pd.5516
2019-07-22
Prenatal Diagnosis
Abstract:ObjectiveN‐acetyltransferase (NAT2) is a phase‐II xenobiotic‐metabolizing enzyme participating in the detoxification of toxic arylamines and aromatic amines. The present study was designed to investigate whether maternal NAT2 genetic polymorphisms are associated with foetal susceptibility to congenital heart diseases (CHDs) and to assess whether the risk is modified by polycyclic aromatic hydrocarbons (PAHs) exposure. MethodsWe conducted a hospital‐based case‐control study to investigate the association of NAT2 gene polymorphisms (rs1799930 G/A, rs1208 A/G, rs1799931 G/A) and the combinations of PAHs exposure and genetic variants with the risk of CHDs. Three hundred and fifty‐seven mothers of CHDs foetuses and 270 control mothers were recruited. Logistic regression models for the risk of CHDs were applied to determine the effect of NAT2 polymorphisms, as well as gene‐exposure interactions. ResultsOur study did not demonstrate an association of maternal NAT2 genetic polymorphisms alone with CHDs occurrence. However, we found that certain genetic polymorphisms of NAT2 in the present of high PAHs exposure have a higher risk of CHDs. ConclusionOur study suggests that the risk of CHDs associated with maternal NAT2 gene polymorphisms is potentiated by PAHs exposure.
genetics & heredity,obstetrics & gynecology
What problem does this paper attempt to address?